Codelivery of survivin inhibitor and chemotherapeutics by tumor‐derived microparticles to reverse multidrug resistance in osteosarcoma. (10th November 2020)

• Record Type: Journal Article
• Authors: Wei, Daiqing; Li, Cui; Ye, Junwu; Xiang, Feifan; Xu, Yangbo; Liu, Juncai
• Is Part Of: Cell biology international. Volume 45:Number 2(2021)
• Page Start: 382
• Page End: 393
• Publication Date: 2020-11-10
• Subjects: chemoresistance -- CIS -- DOX -- MPs -- MTX -- osteosarcoma -- survivin -- toxicity -- YM‐115; Cytology -- Periodicals; Cells -- Periodicals; 571.605
• DOI: 10.1002/cbin.11494
• Languages: English
• ISSNs: 1065-6995

Abstract

Abstract: Reportedly, the elevated expression of survivin has been observed in several tumor types, strictly involved in tumor development. In the present study, we detected elevated survivin expression in tumor tissues derived from patients with chemoresistant osteosarcoma when compared with those from chemosensitive patients. Importantly, knockdown of survivin in osteosarcoma cells significantly suppressed cell proliferation and chemoresistance both in vitro and in vivo. Simultaneously, chemotherapy mediates the upregulation of survivin in osteosarcoma cells through a survivin‐based selective killing effect, resulting in the development of multidrug resistance. The utilization of tumor‐derived microparticles to coencapsulate the survivin inhibitor YM155 and chemotherapeutic agents could effectively reverse multidrug resistance, leading to improved anticancer effects, as well as reduced systemic toxicity. In summary, the expression of survivin contributes to resistance toward osteosarcoma drugs, whereas employing survivin inhibiting combination therapy, based on a microparticle codelivery system, could efficiently reverse resistance and avoid potential systemic toxicity.